Upregulation of NPC1 and its association with poor prognosis in gastric cancer
Authors:
- 2 May 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (10) , 2665-2673
Abstract
Background The Niemann–Pick disease type C1 (NPC1) protein plays a pivotal role in lipid transport, particularly free cholesterol, within lysosomal/late endosomal membranes. Previous studies have highlighted NPC1 as a promising target for cholesterol trafficking and cancer therapy. Nevertheless, the expression of NPC1 in gastric cancer (GC) and its clinical implications remain unexplored. This study aims to investigate NPC1 expression in GC and its correlation with patient prognosis. Methods NPC1 expression levels in GC and normal tissues were assessed using the GEPIA database, and survival analysis was conducted via Kaplan‒Meier Plotter. Evaluation of potential biological effects of NPC1 in GC by protein–protein interaction network and GO, KEGG bioenrichment analysis. Immunohistochemistry was performed on surgical samples collected from 306 GC patients. Correlations between NPC1 expression, clinical characteristics, and patient prognosis were analyzed. Results NPC1 mRNA expression was elevated in GC tissues compared to normal tissues (P < 0.05) and significantly associated with poorer prognosis. In our cohort of 306 patients, NPC1 exhibited significant upregulation in GC versus adjacent normal tissues (P = 0.031). High NPC1 expression correlated with adverse clinical characteristics, including lymph node metastasis, distant metastasis, and advanced TNM stage (all P < 0.05). Patients with high NPC1 expression experienced notably shorter overall survival (P < 0.001), particularly in stages III and IV (P = 0.003). Multivariate Cox regression analysis identified high NPC1 expression as an independent prognostic factor for GC patients (HR 1.57, 95% CI 1.14–2.18, P = 0.006). Lastly, an optimized nomogram incorporating NPC1, tumor size, and TNM stage was constructed. Conclusions NPC1 expression is upregulated in GC and serves as a pivotal prognostic factor for adverse outcomes in GC patients.Keywords
Funding Information
- National Natural Science Foundation of China (81802342)
- Guangzhou Municipal Science and Technology Project (2023A04J2208)
- Kelin New Star of the First Affiliated Hospital of Sun Yat‐Sen University (R08010)
This publication has 26 references indexed in Scilit:
- Hepatocellular carcinoma as a complication of Niemann‐Pick disease type C1American Journal of Medical Genetics Part A, 2021
- Cholesterol-associated lysosomal disorder triggers cell death of hematological malignancy: Dynamic analysis on cytotoxic effects of LW-218Acta Pharmaceutica Sinica B, 2021
- Cholesterol metabolism: New functions and therapeutic approaches in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Clinical relevance of cholesterol homeostasis genes in colorectal cancerBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2019
- Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growthCancer Letters, 2017
- Cell membrane modulation as adjuvant in cancer therapyCancer Treatment Reviews, 2017
- Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola InfectionCell, 2016
- Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RILeukemia Research, 2016
- Lipid rafts as major platforms for signaling regulation in cancerAdvances in Biological Regulation, 2015
- Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytesEuropean Journal of Immunology, 2000